Skip to content

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications

  • Chad Cipiti

Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

Read more

TAGline Spring 2018

  • Chad Cipiti

Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.

Read more

Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy

  • Chad Cipiti

Introduction For many HIV-positive people—particularly those who initiate treatment soon after infection—combination antiretroviral therapy (ART) is associated with robust improvements in CD4+ T cell counts, enhanced immune function, and a life expectancy comparable to that of similar HIV-negative individuals. But a…

Read more
Back To Top